Abstract
Hypoxia is a fetal stressor that leads to the production of endothelin-1 (ET-1). Previous work has shown that ET-1 treatment leads to the premature terminal differentiation of fetal cardiomyocytes. However, the precise mechanism is unknown. We tested the hypothesis that the fetal cardiomyocyte proteome will be greatly altered due to ET-1-treatment, which reveals a potential molecular mechanism of ET-1-induced terminal differentiation. Over a thousand proteins were detected in the fetal cardiomyocytes and among them 75 proteins were significantly altered due to ET-1 treatment. Using IPA pathway analysis, the merged network depicted several key proteins that appeared to be involved in regulating proliferation, including: EED, UBC, ERK1/2, MAPK, Akt, and EGFR. EED protein, which is associated with regulating proliferation via epigenetic mechanisms, is of particular interest. Herein we propose a model of the molecular mechanism by which ET-1 induced cardiomyocyte terminal differentiation occurs.
Keywords: Cardiomyocyte, Endothelin-1, EED, Fetal, Heart, Proliferation, Proteome.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:Proteomic Analysis of Endothelin-1 Targets in the Regulation of Cardiomyocyte Proliferation
Volume: 17 Issue: 15
Author(s): Alexandra N. Shin, Chiranjib Dasgupta, Guangyu Zhang, Kala Seal and Lubo Zhang*
Affiliation:
- Center for Perinatal Biology, Division of Pharmacology, Department of Basic Sciences, Loma Linda University School of Medicine, Loma Linda, CA 92350,United States
Keywords: Cardiomyocyte, Endothelin-1, EED, Fetal, Heart, Proliferation, Proteome.
Abstract: Hypoxia is a fetal stressor that leads to the production of endothelin-1 (ET-1). Previous work has shown that ET-1 treatment leads to the premature terminal differentiation of fetal cardiomyocytes. However, the precise mechanism is unknown. We tested the hypothesis that the fetal cardiomyocyte proteome will be greatly altered due to ET-1-treatment, which reveals a potential molecular mechanism of ET-1-induced terminal differentiation. Over a thousand proteins were detected in the fetal cardiomyocytes and among them 75 proteins were significantly altered due to ET-1 treatment. Using IPA pathway analysis, the merged network depicted several key proteins that appeared to be involved in regulating proliferation, including: EED, UBC, ERK1/2, MAPK, Akt, and EGFR. EED protein, which is associated with regulating proliferation via epigenetic mechanisms, is of particular interest. Herein we propose a model of the molecular mechanism by which ET-1 induced cardiomyocyte terminal differentiation occurs.
Export Options
About this article
Cite this article as:
Shin N. Alexandra, Dasgupta Chiranjib, Zhang Guangyu, Seal Kala and Zhang Lubo*, Proteomic Analysis of Endothelin-1 Targets in the Regulation of Cardiomyocyte Proliferation, Current Topics in Medicinal Chemistry 2017; 17 (15) . https://dx.doi.org/10.2174/1568026617666161116142417
DOI https://dx.doi.org/10.2174/1568026617666161116142417 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Electrochemical-Based Biosensors: New Diagnosis Platforms for Cardiovascular Disease
Current Medicinal Chemistry Pharmacogenomic Considerations in the Treatment of the Pediatric Cardiomyopathy Called Barth Syndrome
Recent Patents on Biotechnology Understanding the Cardiovascular Actions of Soy Isoflavones: Potential Novel Targets for Antihypertensive Drug Development
Cardiovascular & Hematological Disorders-Drug Targets The Role of Trimetazidine After Acute Myocardial Infarction
Current Vascular Pharmacology Occurrence and Clinical Impact of Microembolic Signals (MES) in Patients with Chronic Cardiac Diseases and Atheroaortic Plaques - A Systematic Review
Current Vascular Pharmacology Bone Marrow Stem Cell Therapy for Myocardial Angiogenesis
Current Vascular Pharmacology Left Ventricular Hypertrophy in Isolated Aortic Stenosis: Primetime for the Ventricle
Current Pharmaceutical Biotechnology Insulin Resistance, Oxidative Stress and Cardiovascular Complications: Role of Sirtuins
Current Pharmaceutical Design Patent Selections
Recent Patents on Regenerative Medicine The Chaperone-like Activity of Rat HspB8/Hsp22 and Dynamic Molecular Transition Related to Oligomeric Architectures In Vitro
Protein & Peptide Letters The Biochemical Mechanisms of T-Cell Anergy
Current Immunology Reviews (Discontinued) Understanding Abnormal c-JNK/p38MAPK Signaling in Amyotrophic Lateral Sclerosis: Potential Drug Targets and Influences on Neurological Disorders
CNS & Neurological Disorders - Drug Targets Non-canonical Molecular Targets for Novel Analgesics: Intracellular Calcium and HCN Channels
Current Neuropharmacology Genetic Lipodystrophies: Models for Insulin Resistance
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Human Heart Failure: A Proteomics Perspective
Current Proteomics Control of Copper Status for Cancer Therapy
Current Cancer Drug Targets COVID-19 and the Challenges of Chemotherapy: The Failure Case of Hydroxychloroquine in the Clinical Treatment of SARS-CoV-2 Infection
Coronaviruses Iatrogenic QT Abnormalities and Fatal Arrhythmias: Mechanisms and Clinical Significance
Current Cardiology Reviews Therapeutic and Protective Potential of Mesenchymal Stem Cells, Pharmaceutical Agents and Current Vaccines Against COVID-19
Current Stem Cell Research & Therapy Immunomodulatory Roles of VIP and PACAP in Models of Multiple Sclerosis
Current Pharmaceutical Design